Glycogen Synthase Kinase-3 Inhibitors Reverse Deficits in Long-term Potentiation and Cognition in Fragile X Mice

[1]  M. Dierssen,et al.  Targeting the endocannabinoid system in the treatment of fragile X syndrome , 2013, Nature Medicine.

[2]  Michael R. Hunsaker,et al.  The operation of pattern separation and pattern completion processes associated with different attributes or domains of memory , 2013, Neuroscience & Biobehavioral Reviews.

[3]  C. Bagni,et al.  Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. , 2012, The Journal of clinical investigation.

[4]  Michael R. Hunsaker,et al.  CGG trinucleotide repeat length modulates neural plasticity and spatiotemporal processing in a mouse model of the fragile X premutation , 2012, Hippocampus.

[5]  M. Bear,et al.  Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial , 2012, Science Translational Medicine.

[6]  E. Klann,et al.  Fragile X Syndrome Therapeutics S(C)TEP through the Developmental Window , 2012, Neuron.

[7]  Mark F Bear,et al.  The pathophysiology of fragile X (and what it teaches us about synapses). , 2012, Annual review of neuroscience.

[8]  M. Bear,et al.  Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice , 2012, Neuron.

[9]  C. B. Smith,et al.  Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome , 2012, Neurobiology of Disease.

[10]  G. Collingridge,et al.  A pivotal role of GSK-3 in synaptic plasticity , 2012, Front. Mol. Neurosci..

[11]  B. Christie,et al.  NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice , 2012, Hippocampus.

[12]  Xinyu Zhao,et al.  Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. , 2012, Human molecular genetics.

[13]  C. Pérez,et al.  Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. , 2011, Journal of medicinal chemistry.

[14]  R. Jope,et al.  Glycogen Synthase Kinase-3: A Promising Therapeutic Target for Fragile X Syndrome , 2011, Front. Mol. Neurosci..

[15]  R. Jope.  Glycogen Synthase Kinase-3 in the Etiology and Treatment of Mood Disorders , 2011, Front. Mol. Neurosci..

[16]  C. B. Smith,et al.  Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. , 2011, The international journal of neuropsychopharmacology.

[17]  P. Jin,et al.  Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning , 2011, Nature Medicine.

[18]  D. Kooy,et al.  Genetic Deletion of Regulator of G-protein Signaling 4 (rgs4) Rescues a Subset of Fragile X Related Phenotypes in the Fmr1 Knockout Mouse Keywords: Autism Fragile X Syndrome Gaba B Regulator of G Protein Signaling 4 G-protein Coupled Receptor , 2022 .

[19]  B. Trommer,et al.  Fragile X mice: Reduced long‐term potentiation and N‐Methyl‐D‐Aspartate receptor‐mediated neurotransmission in dentate gyrus , 2011, Journal of neuroscience research.

[20]  Janice Branson,et al.  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.

[21]  Aaron J. Bell,et al.  Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment , 2010, Brain Research.

[22]  R. Jope,et al.  Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. , 2010, Biochimica et biophysica acta.

[23]  T. Lanthorn,et al.  Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments , 2010, Genes, brain, and behavior.

[24]  Zhen Yan,et al.  Regulation of AMPA Receptor Trafficking and Function by Glycogen Synthase Kinase 3* , 2010, The Journal of Biological Chemistry.

[25]  S. Chattarji,et al.  Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome , 2010, Proceedings of the National Academy of Sciences.

[26]  R. Jope,et al.  GSK3 Influences Social Preference and Anxiety-Related Behaviors during Social Interaction in a Mouse Model of Fragile X Syndrome and Autism , 2010, PloS one.

[27]  J. Sweatt,et al.  Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. , 2010, Biochemical pharmacology.

[28]  Richard E Thompson,et al.  Autism spectrum disorder in fragile X syndrome: A longitudinal evaluation , 2009, American journal of medical genetics. Part A.

[29]  D. Loesch,et al.  Behavioural and cognitive phenotypes in idiopathic autism versus autism associated with fragile X syndrome. , 2009, Journal of child psychology and psychiatry, and allied disciplines.

[30]  K. Broadie,et al.  The Fragile X Mental Retardation Protein in Circadian Rhythmicity and Memory Consolidation , 2009, Molecular Neurobiology.

[31]  R. Jope,et al.  Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potential , 2009, Neuropharmacology.

[32]  Deborah D. Hatton,et al.  Memory skills of boys with fragile X syndrome. , 2008, American journal of mental retardation : AJMR.

[33]  R. Kesner,et al.  The role of the dentate gyrus, CA3a,b, and CA3c for detecting spatial and environmental novelty , 2008, Hippocampus.

[34]  Michael R. Hunsaker,et al.  Evaluating the differential roles of the dorsal dentate gyrus, dorsal CA3, and dorsal CA1 during a temporal ordering for spatial locations task , 2008, Hippocampus.

[35]  I. Weiler,et al.  Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome , 2008, Journal of developmental and behavioral pediatrics : JDBP.

[36]  Chris I. De Zeeuw,et al.  Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice , 2008, Neurobiology of Disease.

[37]  M. Bear,et al.  Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome , 2008, The Journal of physiology.

[38]  Michael R. Hunsaker,et al.  The interactions and dissociations of the dorsal hippocampus subregions: how the dentate gyrus, CA3, and CA1 process spatial information. , 2008, Behavioral neuroscience.

[39]  D. Standaert,et al.  Biochemical Fractionation of Brain Tissue for Studies of Receptor Distribution and Trafficking , 2008, Current protocols in neuroscience.

[40]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[41]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[42]  Jian-Guo Chen,et al.  Activation of Glycogen Synthase Kinase-3 Inhibits Long-Term Potentiation with Synapse-Associated Impairments , 2007, The Journal of Neuroscience.

[43]  R. Kesner,et al.  Role of CA3 and CA1 subregions of the dorsal hippocampus on temporal processing of objects , 2007, Neurobiology of Learning and Memory.

[44]  M. Wilson,et al.  Dentate Gyrus NMDA Receptors Mediate Rapid Pattern Separation in the Hippocampal Network , 2007, Science.

[45]  Zhen Yan,et al.  Glycogen Synthase Kinase 3 Regulates N-Methyl-d-aspartate Receptor Channel Trafficking and Function in Cortical Neurons , 2007, Molecular Pharmacology.

[46]  G. Collingridge,et al.  LTP Inhibits LTD in the Hippocampus via Regulation of GSK3β , 2007, Neuron.

[47]  T. Bliss,et al.  Glycogen synthase kinase‐3 inhibition is integral to long‐term potentiation , 2007, The European journal of neuroscience.

[48]  S. Warren,et al.  Transcription, translation and fragile X syndrome. , 2006, Current opinion in genetics & development.

[49]  E. Rolls,et al.  A computational theory of hippocampal function, and empirical tests of the theory , 2006, Progress in Neurobiology.

[50]  Michael R. Hunsaker,et al.  Dissociating the role of the parietal cortex and dorsal hippocampus for spatial information processing. , 2005, Behavioral neuroscience.

[51]  Yan Wang,et al.  Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome , 2005, Neuron.

[52]  R. E. Brown,et al.  A phenotypic and molecular characterization of the fmr1‐tm1Cgr Fragile X mouse , 2004, Genes, brain, and behavior.

[53]  S. Puglisi‐Allegra,et al.  Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex , 2004, Behavioural pharmacology.

[54]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[55]  R. Kooy,et al.  Genetic modifiers in mice: the example of the fragile X mouse model , 2004, Cytogenetic and Genome Research.

[56]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[57]  Mark F. Bear,et al.  Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[58]  C. Pérez,et al.  First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. , 2002, Journal of medicinal chemistry.

[59]  J. Wilding,et al.  [A neuropsychological and behavioural profile of attention deficits in fragile X syndrome]. , 2001, Revista de neurologia.

[60]  W. Brown,et al.  Fmr1 knockout mouse has a distinctive strain-specific learning impairment , 2000, Neuroscience.

[61]  D. Nelson,et al.  (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. , 2000, Human molecular genetics.

[62]  F. Munir,et al.  Spatial Cognition in Males With Fragile-X Syndrome: Evidence for a Neuropsychological Phenotype , 1999, Cortex.

[63]  S. T. Warren,et al.  Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function , 1999, Neuroscience.

[64]  B. Oostra,et al.  Learning and memory in the FMR1 knockout mouse. , 1999, American journal of medical genetics.

[65]  M. Hasselmo,et al.  The hippocampus as an associator of discontiguous events , 1998, Trends in Neurosciences.

[66]  R. C. Honey,et al.  Hippocampal Lesions Disrupt an Associative Mismatch Process , 1998, The Journal of Neuroscience.

[67]  C. Stevens,et al.  Heterogeneity of Release Probability, Facilitation, and Depletion at Central Synapses , 1997, Neuron.

[68]  R. D'Hooge,et al.  Mildly impaired water maze performance in maleFmr1 knockout mice , 1997, Neuroscience.

[69]  R. D'Hooge,et al.  Transgenic mouse model for the fragile X syndrome. , 1996, American journal of medical genetics.

[70]  R. D'Hooge,et al.  Long-term potentiation in the hippocampus of fragile X knockout mice. , 1996, American journal of medical genetics.

[71]  Guy Nagels,et al.  Fmr1 knockout mice: A model to study fragile X mental retardation , 1994, Cell.

[72]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[73]  R. Hagerman,et al.  Cognitive profiles of boys with the fragile X syndrome. , 1988, American journal of medical genetics.

[74]  E. Berry-Kravis,et al.  Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond , 2012, Neuropsychopharmacology.

[75]  J. Lauterborn,et al.  Fragile X syndrome and targeted treatment trials. , 2012, Results and problems in cell differentiation.

[76]  R. Paylor,et al.  Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome , 2011, Psychopharmacology.

[77]  Sanne de Wit,et al.  Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse , 2002, Hippocampus.